Investors

Edesa Biotech – Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases.

Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immunity responses. EB05 (paridiprubart) inhibits Toll-like receptor 4 (TLR4), a key immune signaling protein and an important mediator of inflammation. We are currently evaluating EB05 as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life threatening form of respiratory failure.  This program is funded, in part, by the federal Strategic Innovation Fund. Based in part on the Phase 2 results  of our Phase 2/3 study, the U.S. FDA granted us Fast Track designation.

We are also developing product candidates for a number of chronic dermatological and inflammatory conditions. We recently reported results of a Phase 2b study of our EB01 (daniluromer) drug candidate in moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common, often work-related skin condition. We have an approved clinical trial application for our EB06 monoclonal antibody candidate to conduct a future Phase 2 study in vitiligo. We are also preparing an IND for our EB07 product candidate (paridiprubart) to conduct a future Phase 2 study in patients with fibrotic diseases such as interstitial lung disease associated with systemic sclerosis (SSc-ILD).

Edesa is a clinical-stage biopharma company focused on host-directed therapeutics for immuno-inflammatory diseases

Financial Reports

Investors News

News Alerts

Investors Relations

Edesa Biotech, Inc.
Attn: Investor Relations
100 Spy Court
Markham, ON L3R 5H Canada

(289) 800.9600
investors@edesabiotech.com

Auditor

MNP LLP

Legal Counsel

Fasken Martineau DuMoulin LLP

 

Transfer Agent

Computershare Investor Services Inc.
100 University Avenue, 8th Floor
Toronto, Ontario M5J 2Y1

Tel: (800) 564-6253